Clinical Trials in Arizona

Showing 7261-7280 of 12,706 trials

Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

NCT01423110

This study will assess the efficacy, safety and tolerability of BYM338 in patients with sporadic Inclusion Body Myositis

Sporadic Inclusion Body Myositis

Novartis Pharmaceuticals14 participantsStarted Aug 2011

Scottsdale, Arizona, United States • Kansas City, Kansas, United States • Boston, Massachusetts, United States

COMPLETEDPhase 1/231 miles

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

NCT00708292

This is a Phase I-Ib/II, open-label, multicenter study of AUY922 administered intravenously in patients with multiple myeloma to determine the maximum tolerated dose. The Phase II part will investigate the efficacy of AUY922 in patients with multiple myeloma. Additionally, the study includes a Phase Ib combination part of AUY922 administered in combination with bortezomib, to determine the maximum tolerated dose of the combination drugs in patients with multiple myeloma.

Relapsed or Refractory Multiple Myeloma

Novartis Pharmaceuticals29 participantsStarted Jul 2008

Scottsdale, Arizona, United States • San Antonio, Texas, United States • Melbourne, Australia +6 more locations

COMPLETEDPhase 338 miles

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain

NCT02793817

The primary objective of the study is to investigate the efficacy and safety of KPI-121 1.0% ophthalmic suspension compared to placebo in subjects who have undergone cataract surgery.

Post Surgical Ocular Inflammation and Pain

Kala Pharmaceuticals, Inc.520 participantsStarted Jun 2016

Chandler, Arizona, United States • Phoenix, Arizona, United States • Artesia, California, United States +32 more locations

Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain

Find Trials by Condition in Arizona

PRESERVE-Zenith® Branch Endovascular Graft-Iliac Bifurcation

Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis

Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)

An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis

Using SMART Design to Improve Symptom Management Strategies Among Cancer Patients

LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

Evaluation of Biomarkers of Traumatic Brain Injury

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder

Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function

A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications

Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis

Efficacy and Safety of BGG492 in the Treatment of Migraine

The CDR Implementation Trial

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)